<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626921</url>
  </required_header>
  <id_info>
    <org_study_id>CNMAu8.201LTE</org_study_id>
    <nct_id>NCT04626921</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis</brief_title>
  <acronym>VISIONMS-LTE</acronym>
  <official_title>VISIONARY-MS LTE: A Multi-Center, Open-Label Long-Term Extension Study Assessing the Safety, Efficacy, Tolerability, and Pharmacokinetics of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clene Nanomedicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clene Nanomedicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, long-term extension study available to participants who have completed&#xD;
      CNMAu8.201.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, long-term extension study is only available to participants who have&#xD;
      completed CNMAu8.201 (VISIONARY-MS). The Week 48/End-of-Study Visit for study CNMAu8.201&#xD;
      (VISIONARY-MS) will serve to establish the Baseline for electrophysiological, functional,&#xD;
      morphological vision testing, as well as the neurological and outcome assessments.&#xD;
      Participants will receive open-label CNM-Au8 throughout the study. All participants will&#xD;
      receive a daily dose of 30 mg CNM-Au8 for the entire open-label, long-term extension study.&#xD;
      The dose for participants may be adjusted once efficacy and safety data from study CNMAu8.201&#xD;
      becomes available, which may occur after participants have already started this study. Based&#xD;
      upon a review of data and Sponsor or PI recommendation, this open-label, long-term extension&#xD;
      study may be discontinued once each participant reaches her/his 48-week visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label, Long-Term Extension.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None, open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Best-Corrected Low-Contrast Letter Acuity score.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in BC-LCLA from baseline to end of study across all eyes as measured by 2.5% low contrast Sloan Letter Chart.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent AEs throughout the study.</measure>
    <time_frame>2 years</time_frame>
    <description>Safety endpoint include incidence of treatment-emergent AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of neurological function assessed by a functional composite responder analysis.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in Functional Composite Responder Analysis Score from Baseline to End of Study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in best corrected Low-Contrast Letter Acuity score for total number of correct letter.</measure>
    <time_frame>2 years</time_frame>
    <description>BC-LCLA score is the sum of all correctly identified letters up to the last line on the 2.5% Sloan Chart able in which three (3) or more letters are correctly read plus all correct letters on the following line. Scale is 70 - 0 with 70 being able to see all letters, 0 was unable to read any letters.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Best Corrected High Contrast Visual Acuity</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change from Baseline in best-corrected high contrast visual acuity (BCHCVA), as measured by EDTRS in the affected and fellow eye. Scale is 70 - 0 with 70 being able to see all letters, 0 was unable to read any letters.</description>
  </other_outcome>
  <other_outcome>
    <measure>VEP latency for Multi-Focal visual evoked potential.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in average mf-VEP latency for the affected eye from the average Baseline mf-VEP latency of the affected eye.</description>
  </other_outcome>
  <other_outcome>
    <measure>VEP latency for Full Field Visual Evoked Potential</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in average ff-VEP latency for the affected eye from the average Baseline ff-VEP latency of the affected eye.</description>
  </other_outcome>
  <other_outcome>
    <measure>VEP Amplitude for Multi-Focal Visual Evoked Potential</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in average amplitude for the affected eye from the average Baseline of the affected eye (for all measurable segments).</description>
  </other_outcome>
  <other_outcome>
    <measure>VEP Amplitude for Full Field Visual Evoked Potential</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in average amplitude for the affected eye from the average Baseline of the affected eye (for all measurable segments).</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT of the Retinal Nerve Fiber Layer (RNFL) by Peripapillary Scan</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage change in average thicknesses of the RNFL for the affected eye and the fellow eye from their respective Baselines.</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT of the Retinal Layers by Macular Scan evaluating Ganglion cell and inner plexiform.</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage change in mean thicknesses of the GCIP for the affected eye and the fellow eye from their respective Baselines as determined by segmentation of SD-OCT.</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT of the Retinal Layers by Macular Scan evaluating Ganglion cell layer.</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage change in mean thicknesses of the GCL for the affected eye and the fellow eye from their respective Baselines as determined by segmentation of SD-OCT.</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT of the Retinal Layers by Macular Scan evaluating Inner nuclear layer.</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage change in mean thicknesses of the inner nuclear layer for the affected eye and the fellow eye from their respective Baselines as determined by segmentation of SD-OCT.</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT of the Retinal Layers by Macular Scan evaluating outer nuclear layer.</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage change in mean thicknesses of the outer nuclear layer for the affected eye and the fellow eye from their respective Baselines as determined by segmentation of SD-OCT.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Mean change in whole brain and OR T2 lesion volume.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in whole brain and OR T2 lesion volume from Baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Mean change in whole brain and optic radiation T1 hypo-intense lesion volume.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in whole brain and optic radiation T1 hypointense lesion volume from Baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Proportion of Baseline Gd+ lesions converting to black holes.</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of Baseline Gd+ lesions converting to black holes.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Volume of Baseline Gd+ lesions converting to T1 hypointense lesions.</measure>
    <time_frame>2 years</time_frame>
    <description>Volume of Baseline Gd+ lesions converting to T1 hypointense lesions.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Mean percent whole brain volume change (PBVC) from baseline.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean percent whole brain volume change (PBVC) from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Mean Percent Cerebral Cortical Change from Baseline</measure>
    <time_frame>2 years</time_frame>
    <description>Mean Percent Cerebral Cortical Change from Baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Mean Percent Thalamic Volume Change from Baseline.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean Percent Thalamic Volume Change from Baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Mean Percent Deep Grey Nuclei Volume Change from Baseline.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean Percent Deep Grey Nuclei Volume Change from Baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI Evaluation of the Mean change in number of whole brain new/enlarging T2 lesion(s) from baseline.</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change in number of whole brain new/enlarging T2 lesion(s) from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean change in whole brain DTI/MTR from baseline.</measure>
    <time_frame>2 years</time_frame>
    <description>DTI- Diffusion Tensor Imaging, MTR- Magnetization Transfer Ratio.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean change in optic radiation lesional/non-lesional fibre DTI / MTR difference from Baseline (fiber based, individually reported for each baseline OR lesion).</measure>
    <time_frame>2 years</time_frame>
    <description>Individual OR lesion MRI analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean change in MWF from Baseline in the whole brain.</measure>
    <time_frame>2 years</time_frame>
    <description>Myelin Water Fraction MRI Analysis</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Active treatment with 30 mg of CNM-Au8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highly pure elemental Au nanocrystals are suspended in deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) concentrated up to 0.5 mg/mL (500 ppm) Au.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNM-Au8</intervention_name>
    <description>30 mg of CNM-Au8</description>
    <arm_group_label>Active treatment with 30 mg of CNM-Au8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have completed study CNMAu8.201.&#xD;
&#xD;
          -  Able to understand and give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of treatment compliance during participation in the CNMAu8.201 (VISIONARY-MS)&#xD;
             study.&#xD;
&#xD;
          -  Positive pregnancy test.&#xD;
&#xD;
          -  Any history of previous malignancy, with the exception of basal cell carcinoma of the&#xD;
             skin or in situ carcinoma of the cervix, post documented full resections, with clean&#xD;
             margins.&#xD;
&#xD;
          -  Based on the Investigator's judgment, any concurrent chronic or acute illness or&#xD;
             unstable medical condition that could confound the results of safety assessments,&#xD;
             increase risk to the participant, or lead to difficulty complying with the protocol;&#xD;
             any untreated or unstable psychiatric disease including depression, bipolar and&#xD;
             psychosis.&#xD;
&#xD;
          -  Participant is considered a suicide risk in the opinion of the Investigator, has&#xD;
             previously made a suicide attempt, or is currently demonstrating active suicidal&#xD;
             ideation.&#xD;
&#xD;
        Following clinical and serology sample analysis conducted at the end-of-study visit for&#xD;
        CNMAu8.201 (VISIONARY-MS), participants may be removed from this long term extension study&#xD;
        if any of the following criteria are met, at the discretion of the Medical Monitor and/or&#xD;
        Sponsor's Medical Representative:&#xD;
&#xD;
          -  Positive serology for viral hepatitis B and/or C and/or human immunodeficiency virus&#xD;
             (HIV).&#xD;
&#xD;
          -  Abnormal liver function tests (aspartate aminotransferase [ASAT] or alanine&#xD;
             aminotransferase [ALAT] &gt; 2x upper limit of normal range (ULN) or total bilirubin &gt; 2x&#xD;
             ULN or alkaline phosphatase (AP) &gt; 3x ULN).&#xD;
&#xD;
          -  Participants with clinically significant hepatic or renal dysfunction or clinical&#xD;
             laboratory findings that would limit the interpretability of change in liver or kidney&#xD;
             function (e.g., glomerular filtration rate &lt; 40 mL/min [based on creatinine clearance&#xD;
             according to Cockcroft-Gault equation]), or those with low platelet counts (&lt;150 x 109&#xD;
             per liter) or eosinophilia (absolute eosinophil count of ≥500 eosinophils per&#xD;
             microliter) at the EOS visit for CNMAu8.201 (Visionary-MS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sydney Brain Mind Centre</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Leonards Hill</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menzies Institute for Medical Research</name>
      <address>
        <city>Hobart</city>
        <state>TAZ</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth</city>
        <state>Vale</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health Department of Neurology</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Centre Department of Neuroscience</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Perron Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>RMS</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Demyelination</keyword>
  <keyword>Remyelination</keyword>
  <keyword>Optic Neuropathy</keyword>
  <keyword>Optic Neuritis</keyword>
  <keyword>Gold</keyword>
  <keyword>Nanocrystal</keyword>
  <keyword>Multifocal VEP</keyword>
  <keyword>Full Field VEP</keyword>
  <keyword>Low contrast letter acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

